Claims for RU <strong>486</strong>/PG Abortionfrom April 1990 <strong>and</strong> confirmed by the April 1991 Frenchwoman’s death blamed on cardiovascular complicationscaused by ‘heavy smoking’.Increasingly, there are more <strong>and</strong> more contraindicationsadded to the list Obesity is now identified as an additionalfactor detracting from the RU <strong>486</strong>/PG success rates (Vervest<strong>and</strong> Haspels, 1985:627; Cameron <strong>and</strong> Baird, 1986:273;WHO Trial, 1989a: 722; Grimes et al., 1990:913). Moreconditions will certainly be added in the future, restrictingRU <strong>486</strong>/PG to a further diminished population of women.ComplicationsIn a comprehensive review of medical journal articles, weexamined <strong>and</strong> analyzed complications of chemical abortions.These articles covered a span of seven years (1984–90),<strong>and</strong> included the most well-known as well as some of thelesser known research. Because these studies have differentcriteria for measuring success, efficacy, <strong>and</strong> complications,<strong>and</strong> because they often use different protocols within the samestudy, it is difficult to ascertain patterns <strong>and</strong> an agreed-uponsystem of evaluation.The difficulty starts with the definition of age of pregnancy.Most researchers would agree that RU <strong>486</strong>, when used alone,or when used in combination with prostagl<strong>and</strong>ins, worksbest when the pregnancy is less than 42–49 days. There is adisparity in how the 42–49 days figure is arrived at, sincesome researchers count from the first day of the last menstrualperiod (Swahn <strong>and</strong> Bygdeman, 1989); some are not specific,merely stating 42–49 days since the last menstrual period(Somell <strong>and</strong> Ölund, 1990; <strong>and</strong> Grimes et al., 1988); <strong>and</strong> somecount from the expected onset of the last missed menstrualperiod, in which case there are only approximately 14–21days when RU <strong>486</strong>/PG is operational (see Couzinet et al.,1986). Since timing is critical to an RU <strong>486</strong>/PG abortion,the exact age of pregnancy is crucial.There is, however, at least one study that maintains that37
RU <strong>486</strong>the age of pregnancy has no significant effect, provided that itis less than 43 days, on the outcome of treatment (Sitruk-Wareet al., 1990). Additionally, most researchers now contend thatultrasound or measurement of ß-hCG levels are more reliableindicators of the age of pregnancy than a woman’s testimonyregarding her own menstrual cycle. If ultrasound becomesthe preferred measure of assessing the age of pregnancy, thismay result in more complications in third world countrieswhere the equipment may not be available.Incomplete abortions with or without a continuingpregnancy constitute the second complication. In studieswhere RU <strong>486</strong> is used without prostagl<strong>and</strong>in analogues,incomplete abortions/continuing pregnancies ranged from 44per cent (Kovacs, 1984) to 10 per cent (Grimes et al., 1988).Where a combination of RU <strong>486</strong>/PG is used, in the morerecent clinical studies, incomplete abortions/continuingpregnancies ranged from 13.4 per cent (Gao et al., 1988) totwo per cent (Rodger <strong>and</strong> Baird, 1989). However, onewoman in this last-mentioned study required emergencysurgery. Incomplete abortions <strong>and</strong> ongoing pregnancies, ofcourse, necessitate that the products of conception areremoved by conventional abortion methods. Incompleteevacuation can be accompanied by severe bleeding due totissue that remains in the cervical area <strong>and</strong> is usuallyremedied by dilation <strong>and</strong> curettage. One study indicated thata woman who had been classified as a success returned twomonths later because of residual decidual material (Sitruk-Ware et al., 1990:228). This adverse effect of RU <strong>486</strong>/PGabortion may lead to other possible complications such aspelvic inflammatory disease (PID) from infection, toinfertility, <strong>and</strong> possibly uterine cancer.In one study, clinicians administering RU <strong>486</strong> withoutprostagl<strong>and</strong>in analogues ‘adopted a conservative approachwith weekly ß-HCG <strong>and</strong> ultrasound evaluation.’ Theyreported that 29 out of 124 women did not terminate theirpregnancies until ‘between Day 15 <strong>and</strong> Day 45 after38
- Page 2 and 3: Renate Klein is Lecturer in Women
- Page 4 and 5: RU 486Misconceptions,Myths and Mora
- Page 6 and 7: ACKNOWLEDGEMENTSWe would like to ex
- Page 8 and 9: CONTENTSINTRODUCTION 1CHAPTER ONETh
- Page 10 and 11: INTRODUCTIONInitial euphoria greete
- Page 12 and 13: IntroductionUnfortunately, objectio
- Page 14 and 15: Introductiondo not know or do not a
- Page 16 and 17: Introductionused widely for years a
- Page 18 and 19: CHAPTER ONEThe History of RU 486RU
- Page 20 and 21: The History of RU 486consultants ar
- Page 22 and 23: The History of RU 486Events in Fran
- Page 24 and 25: The History of RU 486service of wom
- Page 26 and 27: The History of RU 486The result app
- Page 28 and 29: The History of RU 486developing cou
- Page 30 and 31: The History of RU 486University Hos
- Page 32 and 33: The History of RU 486pharmacovigila
- Page 34 and 35: CHAPTER TWOClaims for RU 486/PG Abo
- Page 36 and 37: Claims for RU 486/PG Abortionsevera
- Page 38 and 39: Claims for RU 486/PG Abortionthe Br
- Page 40 and 41: Claims for RU 486/PG Abortionan imm
- Page 42 and 43: Claims for RU 486/PG Abortionby the
- Page 44 and 45: Claims for RU 486/PG Abortionby the
- Page 48 and 49: Claims for RU 486/PG Abortioncommen
- Page 50 and 51: Claims for RU 486/PG AbortionSome s
- Page 52 and 53: Claims for RU 486/PG Abortionbreeze
- Page 54 and 55: Claims for RU 486/PG Abortion18 per
- Page 56 and 57: Claims for RU 486/PG Abortion1. RU
- Page 58 and 59: Claims for RU 486/PG AbortionRU 486
- Page 60 and 61: Claims for RU 486/PG Abortionwider
- Page 62 and 63: Claims for RU 486/PG Abortionmedica
- Page 64 and 65: Claims for RU 486/PG Abortionreligi
- Page 66 and 67: What Is RU 486 and How Does It Work
- Page 68 and 69: What Is RU 486 and How Does It Work
- Page 70 and 71: What Is RU 486 and How Does It Work
- Page 72 and 73: What Is RU 486 and How Does It Work
- Page 74 and 75: What Is RU 486 and How Does It Work
- Page 76 and 77: What Is RU 486 and How Does It Work
- Page 78 and 79: What Is RU 486 and How Does It Work
- Page 80 and 81: What Is RU 486 and How Does It Work
- Page 82 and 83: What Is RU 486 and How Does It Work
- Page 84 and 85: What Is RU 486 and How Does It Work
- Page 86 and 87: What Is RU 486 and How Does It Work
- Page 88 and 89: What Is RU 486 and How Does It Work
- Page 90 and 91: The Role of Prostaglandins: Known a
- Page 92 and 93: The Role of Prostaglandins: Known a
- Page 94 and 95: The Role of Prostaglandins: Known a
- Page 96 and 97:
The Role of Prostaglandins: Known a
- Page 98 and 99:
The Role of Prostaglandins: Known a
- Page 100 and 101:
The Role of Prostaglandins: Known a
- Page 102 and 103:
The Role of Prostaglandins: Known a
- Page 104 and 105:
The Role of Prostaglandins: Known a
- Page 106 and 107:
The Role of Prostaglandins: Known a
- Page 108 and 109:
The Role of Prostaglandins: Known a
- Page 110 and 111:
The Role of Prostaglandins: Known a
- Page 112 and 113:
The Role of Prostaglandins: Known a
- Page 114 and 115:
The Role of Prostaglandins: Known a
- Page 116 and 117:
The Role of Prostaglandins: Known a
- Page 118 and 119:
The Role of Prostaglandins: Known a
- Page 120 and 121:
The Role of Prostaglandins: Known a
- Page 122 and 123:
ConclusionInstead, Baulieu uses the
- Page 124 and 125:
Conclusionintervention. Thus, RU 48
- Page 126 and 127:
Conclusionbetween population contro
- Page 128 and 129:
ConclusionThis article, appearing i
- Page 130 and 131:
Conclusion‘a whole net of relatio
- Page 132 and 133:
ENDNOTESChapter One1The paten t lic
- Page 134 and 135:
Endnotes12The Journal Officiel publ
- Page 136 and 137:
Endnotesin Gynecology and Obstetric
- Page 138 and 139:
Endnotesof menses. On the third day
- Page 140 and 141:
EndnotesAnother such example is the
- Page 142 and 143:
Bibliographyand Segal, Sheldon (Eds
- Page 144 and 145:
Bibliographyprostaglandin F 2•. A
- Page 146 and 147:
BibliographyDelaney, Anne. (1991, 2
- Page 148 and 149:
Bibliographyresponses to the steroi
- Page 150 and 151:
Bibliographyabnormalities resulting
- Page 152 and 153:
Bibliographyprogesterone receptor b
- Page 154 and 155:
BibliographyOdlind, Viveca and Birg
- Page 156 and 157:
BibliographyBinding of the anti-pro
- Page 158 and 159:
BibliographyUlmann, André, Teutsch
- Page 160:
Bibliographytermination by vacuum a